[Skip to Content]
[Skip to Content Landing]
April 10, 2013

Use of Stem Cells for Ischemic Cardiomyopathy

Author Affiliations

Author Affiliations: Department of Plastic Surgery, 2nd Affiliated Hospital of Wenzhou Medical College, Wenzhou, China (Dr Zhang); Department of Plastic Surgery, 9th People's Hospital of Medical School of Shanghai Jiao Tong University, Shanghai, China (Dr Li); and Wound Healing and Cell Biology Laboratory, First Hospital Affiliated to the PLA General Hospital, Beijing, China (Dr Fu; fuxiaobing@vip.sina.com).

JAMA. 2013;309(14):1458-1459. doi:10.1001/jama.2013.2890

To the Editor: Dr Hare and colleagues1 investigated the efficacy and safety of allogeneic mesenchymal stem cells (MSCs) administered by transendocardial stem cell injection compared with autologous MSCs in patients with chronic left ventricular dysfunction secondary to myocardial infarction. The results are encouraging; however, we have some concerns about the study.